EBITDA: Income before interest, taxes, depreciation and amortization.
Protara Therapeutics, Inc. (TARA) had EBITDA of $-23.25M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
-- |
|
$-21.69M |
|
-- |
|
-- |
|
$23.15M |
|
$-23.15M |
|
$1.47M |
|
$-21.69M |
|
$-21.69M |
|
$-21.69M |
|
$-21.69M |
|
$-21.69M |
|
$-21.69M |
|
$-23.15M |
|
|
EBITDA |
$-23.25M |
62.85M |
|
62.85M |
|
$-0.35 |
|
$-0.35 |
|
| Balance Sheet Financials | |
$129.67M |
|
$1.58M |
|
$26.87M |
|
$156.54M |
|
$14.39M |
|
-- |
|
$1.13M |
|
$15.52M |
|
$141.02M |
|
$141.02M |
|
$141.02M |
|
59.97M |
|
| Cash Flow Statement Financials | |
$-55.17M |
|
$29.14M |
|
$1.53M |
|
$50.40M |
|
$25.89M |
|
$-24.51M |
|
$4.33M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-56.23M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.38% |
|
-15.38% |
|
-13.85% |
|
-15.38% |
|
$2.35 |
|
$-0.89 |
|
$-0.88 |
|